Last reviewed · How we verify

Dexamethasone+NK-1 RA+5-HT3 RA — Competitive Intelligence Brief

Dexamethasone+NK-1 RA+5-HT3 RA (Dexamethasone+NK-1 RA+5-HT3 RA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiemetic combination therapy. Area: Oncology (supportive care).

phase 3 Antiemetic combination therapy Glucocorticoid receptor, NK-1 receptor, 5-HT3 receptor Oncology (supportive care) Small molecule Live · refreshed every 30 min

Target snapshot

Dexamethasone+NK-1 RA+5-HT3 RA (Dexamethasone+NK-1 RA+5-HT3 RA) — Fifth Affiliated Hospital, Sun Yat-Sen University. This triple-agent combination blocks chemotherapy-induced nausea and vomiting (CINV) through corticosteroid anti-inflammatory action, neurokinin-1 receptor antagonism, and serotonin 5-HT3 receptor antagonism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dexamethasone+NK-1 RA+5-HT3 RA TARGET Dexamethasone+NK-1 RA+5-HT3 RA Fifth Affiliated Hospital, Sun Yat-Sen University phase 3 Antiemetic combination therapy Glucocorticoid receptor, NK-1 receptor, 5-HT3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiemetic combination therapy class)

  1. Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexamethasone+NK-1 RA+5-HT3 RA — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-nk-1-ra-5-ht3-ra. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: